Operator: Good day, everyone, and thank you for standing by. My name is RJ, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q3 2025 Xenon Pharmaceuticals, Inc. Earnings Conference Call.
[Operator Instructions]
I would now like to turn the call over to Colleen, Senior— or Xenon Senior Vice President of Corporate Affairs. Please go ahead.
—
**Colleen Alabiso:**
Good afternoon. Thank you for joining us on our call and webcast to discuss Xenon’s third quarter 2025 financial and operating results.
Joining me today are Ian Mortimer, President and Chief Executive Officer; Dr. Chris Kenney, Chief Medical Officer; Darren Cline, Chief Commercial Officer; and Tucker Kelly, our Chief Financial Officer.
After completing our prepared remarks today, we will open the call up for questions.
Please be advised that during this call, we will make a number of forward-looking statements. These include statements regarding the timing of and potential results from clinical trials, the potential efficacy and safety profile of our products, future development plans, current and anticipated indications, addressable markets, regulatory success, and the commercial potential of our and our partners’ product candidates.
We will also discuss the efficacy of our clinical trial designs and our ability to successfully develop and…
https://seekingalpha.com/article/4837165-xenon-pharmaceuticals-inc-xene-q3-2025-earnings-call-transcript?source=feed_all_articles